MULTI-INDICATION BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS IGPRO20 PRE-FILLED SYRINGES FOR THE TREATMENT OF PID, SID, AND CIDP IN ITALY
Author(s)
Batyrkhan Kuatov, MSc1, Alanna MacDonald, BSc, MSc2, Stacey Priest, BSc, MSc2, Diana Tran, BS, MSc2, Laurence UNDREINER, MSc, MBA3, Melike INKAYA TASKIN, BSc, MBA4, Jonathan Galduf, MSc, PharmD5, Sara Villa, MSc6;
1CSL Behring, Bern, Switzerland, 2EVERSANA, Victoria, BC, Canada, 3CSL Behring, Paris, France, 4CSL Behring, ISTANBUL, Turkey, 5CSL BEHRING, S.A., Barcelona, Spain, 6CSL Behring, Milan, Italy
1CSL Behring, Bern, Switzerland, 2EVERSANA, Victoria, BC, Canada, 3CSL Behring, Paris, France, 4CSL Behring, ISTANBUL, Turkey, 5CSL BEHRING, S.A., Barcelona, Spain, 6CSL Behring, Milan, Italy
OBJECTIVES: Diseases treated with immunoglobulins include primary and secondary immunodeficiencies (PID, SID), which compromise immune function, and chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disorder causing progressive limb weakness. Standard treatments have relied on intravenous or subcutaneous immunoglobulins (IVIG, SCIG) delivered in vials. IgPro20 pre-filled syringes (PFS) provide ready-to-use doses that simplify administration and improve operational efficiency. This analysis estimated the budget impact of introducing IgPro20 PFS into an Italian healthcare payer plan for patients with PID, SID, or CIDP.
METHODS: A three-year budget-impact model was developed to compare costs between scenarios with and without IgPro20 PFS, from the Italian healthcare payer perspective. Alternative treatments included IgPro20 vials and IVIG or SCIG baskets, with market shares reflecting real-world clinical practice for each indication. In the IgPro20-PFS scenario, market share primarily shifted from IgPro20 vials, and a smaller proportion from other IVIG and SCIG products. The analysis considered drug acquisition, administration, and adverse event (AE) management costs informed by available literature. Wastage and discounting were excluded.
RESULTS: Over three years, 15,605 PID, SID, and CIDP patients were eligible for treatment. The analysis estimated total cost savings of €31,524,488 for the total population (€8,840,041 in the PID population, €5,413,035 in the SID population, and €17,271,412 in the CIDP population). Results of sensitivity analyses demonstrated the budget impact was most sensitive to the price of IgPro20 PFS and IgPro20 vials.
CONCLUSIONS: This analysis indicates that introducing IgPro20 PFS would generate highly significant cost savings for the Italian healthcare system over three years. Savings are driven by reduced drug acquisition costs due to improved dosing efficiency with IgPro20 PFS, as well as lower administration and AE management costs compared with IVIG therapies. The results support the potential value of IgPro20 PFS as a positive investment for managing patients with PID, SID, and CIDP.
METHODS: A three-year budget-impact model was developed to compare costs between scenarios with and without IgPro20 PFS, from the Italian healthcare payer perspective. Alternative treatments included IgPro20 vials and IVIG or SCIG baskets, with market shares reflecting real-world clinical practice for each indication. In the IgPro20-PFS scenario, market share primarily shifted from IgPro20 vials, and a smaller proportion from other IVIG and SCIG products. The analysis considered drug acquisition, administration, and adverse event (AE) management costs informed by available literature. Wastage and discounting were excluded.
RESULTS: Over three years, 15,605 PID, SID, and CIDP patients were eligible for treatment. The analysis estimated total cost savings of €31,524,488 for the total population (€8,840,041 in the PID population, €5,413,035 in the SID population, and €17,271,412 in the CIDP population). Results of sensitivity analyses demonstrated the budget impact was most sensitive to the price of IgPro20 PFS and IgPro20 vials.
CONCLUSIONS: This analysis indicates that introducing IgPro20 PFS would generate highly significant cost savings for the Italian healthcare system over three years. Savings are driven by reduced drug acquisition costs due to improved dosing efficiency with IgPro20 PFS, as well as lower administration and AE management costs compared with IVIG therapies. The results support the potential value of IgPro20 PFS as a positive investment for managing patients with PID, SID, and CIDP.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE166
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Rare & Orphan Diseases